跳至主要内容
临床试验/ACTRN12621001117808
ACTRN12621001117808招募中未知

Pre-treatment dihydropyrimidine dehydrogenase (DPYD) genotyping to individualise fluoropyrimidine-based chemotherapy: An evaluation of clinical implementation and treatment-related toxicity.

Queensland Health - Metro North Health0 个研究点目标入组 280 人开始时间: 2021年8月23日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • a.Pathologically confirmed malignancy for which treatment with a fluoropyrimidine at full dose (with or without other chemotherapy agents or radiation) is deemed clinically appropriate
  • b.Adult patient (> 18 years)
  • c.Receiving their first dose of fluoropyrimidine (either as a single agent or in combination) between 1 July, 2021 and 30 June, 2022.
  • d.Willing to provide blood sample for pharmacogenetic testing

排除标准

  • a.Inability to provide informed consent
  • b.Prior use of fluoropyrimidines
  • c.Women who are pregnant or breast-feeding
  • d.Patients with a previously known homozygous polymorphic genotype or compound heterozygous genotype for DPYD.

研究者

发起方
Queensland Health - Metro North Health

相似试验

Pre-treatment dihydropyrimidine dehydrogenase (DPYD)... | 临床试验